Endocrine TherapyThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

650 records returned

Survivorship: adult cancer survivors.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
During the next decade, a rapid increase in the number of new cancer diagnoses in the population as well as a growing number of cancer survivors can be expected. Cancer is anticipated to exceed cardiovascular disease as the primary cause of mortality in the United States population. Despite efforts in tobacco control, the aging of the population and obesity epidemic will contribute toward the increasing incidence of cancer. Although oncology specialists will continue to play a critical role in the diagnosis and initial treatment of patients with cancer, primary care providers will need to play an expanding role in the ...
Source: Primary Care - November 17, 2009 Category: Primary Care Authors: Ganz PA Tags: Prim Care Source Type: journals

Randomized Clinical Trials in Breast CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Breast cancer remains the most common cancer diagnosed in women and the second leading cause of cancer-related deaths in this group. Significant advances in the treatment of breast cancer and in the ability to screen for the disease mean that it is also one of the most curable forms of cancer. Long-term updates of the trials reviewed in the previous edition of this article have demonstrated that breast-conserving therapy remains a viable option for most patients, and that local control is related to overall survival. New chemotherapeutic options and endocrine therapies are available to select subsets of patients, and the u...
Source: Surgical Oncology Clinics of North America - November 16, 2009 Category: Surgery Authors: Aimee M. Crago, Michelle Azu, Shannon Tierney, Monica Morrow Source Type: journals

Prognostic factors for and outcome of locally advanced prostate cancer after radical prostatectomyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
To present the outcomes of cT3N0M0 prostate cancer after radical prostatectomy (RP) and determine the prognostic factors in biochemical progression-free survival (BPFS), clinical progression-free survival (CPFS), cancer-specific survival (CSS) and overall survival (OS) after long-term follow-up of 10 years. In all, 164 patients who were assessed as clinical T3 prostate cancer by digital rectal examination (DRE), underwent RP and bilateral pelvic lymphadenectomy at Erasmus MC between 1977 and 2004 without neoadjuvant treatment. Preoperative staging computed tomography showed no signs of metastasis. Kaplan[ndash]Meier curves...
Source: BJU International - November 13, 2009 Category: Urology & Nephrology Authors: Chao-Yu Hsu, Mark F. Wildhagen, Hein Van Poppel, Chris H. Bangma Source Type: journals

Endocrine therapy may cause heart diseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - November 11, 2009 Category: Drugs & Pharmacology Tags: Research article Source Type: journals

Challenges in defining predictive markers for response to endocrine therapy in breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Future Oncology , November 2009, Vol. 5, No. 9, Pages 1415-1428. (Source: Future Oncology)
Source: Future Oncology - November 10, 2009 Category: Cancer & Oncology Tags: article Source Type: journals

Æterna Zentaris: Scientific Article Supports Perifosine?s Development in Kidney CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Article published in December 2009 issue of the Journal of Urology Quebec City, Canada, November 9, 2009 – Æterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the “Company”), a global biopharmaceutical company focused on endocrine therapy... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 9, 2009 Category: Pharmaceuticals Source Type: clinical trials

Clinical relevance of the putative stem cell marker p63 in breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract P63 is a member of the p53 family. This protein is crucial for the maintenance of a stem cell population in the human epithelium and necessary for the normal development of all epithelial tissues including mammary glands. In normal breast tissue, the p63 seems to be a specific myoepithelial cell marker. P63 expression has been described in highly aggressive ER negative basal-like breast tumors. The value of p63 expression in ER positive disease is less clear. The expression levels of p63 mRNA by Affymetrix microarray analysis in a combined cohort of 2,158 ER positive breast cancers and its prognosti...
Source: Breast Cancer Research and Treatment - November 6, 2009 Category: Cancer & Oncology Tags: Breast Cancer Research and Treatment Source Type: journals

Æterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
QUÉBEC CITY, Nov. 2 /CNW Telbec/ - Æterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 2, 2009 Category: Pharmaceuticals Source Type: clinical trials

Æterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
QUÉBEC CITY, Nov. 2 /CNW Telbec/ - Æterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - November 2, 2009 Category: Pharmaceuticals Source Type: clinical trials

Oncologists favour endocrine therapy as age increases and health declines.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 31, 2009 Category: Health Management Tags: Research article Source Type: journals

Endocrine therapy necessary for breast cancer patients with hormone receptor conversionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Non-administration of adjuvant endocrine therapy to breast cancer patients with hormone receptor conversion is associated with a worse prognosis compared with those who receive endocrine therapy, Japanese researchers report. (Source: MedWire News - Breast Cancer)
Source: MedWire News - Breast Cancer - October 31, 2009 Category: Cancer & Oncology Source Type: news

Endocrine therapy necessary for breast cancer patients with hormone receptor conversionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Non-administration of adjuvant endocrine therapy to breast cancer patients with hormone receptor conversion is associated with a worse prognosis compared with those who receive endocrine therapy, Japanese researchers report. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - October 31, 2009 Category: Cancer & Oncology Source Type: news

Additive endocrine therapy for advanced breast cancer - back to the future.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
While novel endocrine treatment options have been implemented in the advanced - as well as adjuvant setting, recent results suggest a place for "old-fashioned" additive treatment with estrogens in advanced breast cancer. This paper reviews the biological rationale for endocrine therapy in general and additive treatment with estrogens in particular. The finding that patients becoming resistant to treatment with aromatase inhibitors may subsequently respond to estrogen therapy adds important information to our understanding of therapy resistance in general. Moreover, the return of a therapeutic option abandoned more than...
Source: Acta Oncologica - October 31, 2009 Category: Cancer & Oncology Authors: Lønning PE Tags: Acta Oncol Source Type: journals

Circulating Tumor Cells: A Useful Predictor of Treatment Efficacy in Metastatic Breast Cancer [Breast Cancer]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion We provide, to our knowledge, the first evidence of a strong correlation between CTC results and radiographic disease progression in patients receiving chemotherapy or endocrine therapy for MBC. These findings support the role of CTC enumeration as an adjunct to standard methods of monitoring disease status in MBC. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 29, 2009 Category: Cancer & Oncology Authors: Liu, Shields, Warren, Cohen, Wilkinson, Ottaviano, Rao, Eng-Wong, Seillier-Moiseiwitsch, Noone, Isaacs Tags: Diagnosis & Staging Breast Cancer Source Type: journals

HDAC Inhibitor SNDX-275 Induces Apoptosis in erbB2-Overexpressing Breast Cancer Cells via Down-regulation of erbB3 ExpressionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Breast cancer is a highly heterogeneous disease with distinct histologic subtypes. Targeted therapies such as endocrine therapy and growth factor receptor inhibitors have had a significant impact on the treatment of metastatic breast cancer patients. Unfortunately, resistance to these agents eventually occurs, and currently represents a significant clinical problem in the management of breast cancers. Inhibitors of histone deacetylases (HDACi) exhibit anticancer activity in a variety of tumor cell models and have been shown to target mechanisms of resistance to a number of targeted agents. It is unclear, however, if there ...
Source: Cancer Research - October 29, 2009 Category: Cancer & Oncology Authors: Huang, X., Gao, L., Wang, S., Lee, C.-K., Ordentlich, P., Liu, B. Tags: Experimental Therapeutics, Molecular Targets, and Chemical Biology Source Type: journals

Third consensus on medical treatment of metastatic breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: The present consensus manuscript updates evidence-based recommendations for state-of-the-art treatment of MBC depending on disease-associated and biological variables. (Source: Annals of Oncology)
Source: Annals of Oncology - October 27, 2009 Category: Cancer & Oncology Authors: Beslija, S., Bonneterre, J., Burstein, H. J., Cocquyt, V., Gnant, M., Heinemann, V., Jassem, J., Kostler, W. J., Krainer, M., Menard, S., Petit, T., Petruzelka, L., Possinger, K., Schmid, P., Stadtmauer, E., Stockler, M., Van Belle, S., Vogel, C., Wilcken Tags: reviews Source Type: journals

Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract Mutations in the alpha catalytic subunit of phosphoinositol-3-kinase (PIK3CA) occur in ~30% of ER positive breast cancers. We therefore sought to determine the impact of PIK3CA mutation on response to neoadjuvant endocrine therapy. Exons 9 (helical domain) and 20 (kinase domain—KD) mutations in PIK3CA were determined samples from four neoadjuvant endocrine therapy trials. Interactions with clinical, pathological, and biomarker response parameters were examined. A weak negative interaction between PIK3CA mutation status and clinical response to neoadjuvant endocrine treatment was detected (N =...
Source: Breast Cancer Research and Treatment - October 21, 2009 Category: Cancer & Oncology Tags: Breast Cancer Research and Treatment Source Type: journals

The Expanding Use of Third-Generation Aromatase Inhibitors: What the General Internist Needs to KnowEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS In situations where patients experience significant negative side effects from AI therapy, discussions to discontinue treatment (and switch to an alternative endocrine therapy) should involve the cancer specialist and take into consideration the patient’s risk for breast cancer recurrence and the impact of therapy on their quality of life. In some cases, patients may choose to never initiate AI treatment. In other cases, patients may choose to prematurely discontinue therapy even if therapy is well tolerated. In both settings increased knowledge by the general internists will likely facilitate ...
Source: Journal of General Internal Medicine - October 17, 2009 Category: Internal Medicine Tags: Journal of General Internal Medicine Source Type: journals

Improving the accuracy of clinical estimation of lesion size using simple measuring adjunctsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Aims: The management of many diseases, including breast cancer, is often influenced by the pre-operative stage or dimension of the tumour. Breast cancer patients treated with primary endocrine therapy are reviewed regularly to assess tumour response, but often by different clinicians. Accurate assessment of lesion size is therefore essential. The aim of this study was to assess the accuracy of clinical sizing of lesions and investigate the impact of two measuring adjuncts on size estimation. (Source: European Journal of Surgical Oncology)
Source: European Journal of Surgical Oncology - October 16, 2009 Category: Cancer & Oncology Authors: Martha Nixon, T. Underwood, N. Coombs Tags: Abstracts Source Type: journals

Surgery versus primary endocrine therapy for elderly women with oestrogen receptor positive early operable primary breast cancer - analysis of causes of deathEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Background: We recently reported survival analysis of a large series of women with ER+ early operable primary breast cancer (1). In women >80 years, surgery and primary endocrine therapy did not produce any difference in breast cancer specific survival, and this appears to be related to the preponderance of strongly ER+ tumours. We now report analysis of causes of death for the same series. (Source: European Journal of Surgical Oncology)
Source: European Journal of Surgical Oncology - October 16, 2009 Category: Cancer & Oncology Authors: Simon Johnston, B. Syed, D. Wong, D. Morgan, K. Cheung Tags: Abstracts Source Type: journals

Surgery versus endocrine therapy for elderly women with oestrogen receptor (ER) positive early operable breast cancer - survival analysis and correlation with oestrogen receptor positivityEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Background: A recent Cochrane review of seven randomised trials involving 1,446 elderly women (unselected for ER) has shown no significant difference in overall survival between surgery and primary endocrine therapy using tamoxifen. We now report results of a large series from a single centre with a dedicated elderly breast cancer service, with long term follow-up. (Source: European Journal of Surgical Oncology)
Source: European Journal of Surgical Oncology - October 16, 2009 Category: Cancer & Oncology Authors: Binafsha Syed, S. Johnston, D. Wong, D. Morgan, I. Ellis, K. Cheung Tags: Abstracts Source Type: journals

Primary endocrine therapy for early operable primary breast cancer in elderly women - A large series from a single institutionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report our experience of using PET in a dedicated elderly breast cancer service. (Source: European Journal of Surgical Oncology)
Source: European Journal of Surgical Oncology - October 16, 2009 Category: Cancer & Oncology Authors: Waleed Al-Khyatt, B. Syed, D. Morgan, K. Cheung Tags: Abstracts Source Type: journals

Prostate Cancer Therapy Raises Cardiovascular RiskEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
BERLIN — Men treated with endocrine therapy for prostate cancer are at increased risk of developing and dying from several types of cardiovascular disease, according to a large observational analysis of 30,642 Swedish patients. (Source: Family Practice News)
Source: Family Practice News - October 15, 2009 Category: Primary Care Authors: PATRICE WENDLING Tags: News Source Type: news

Hormone Tx in Prostate Cancer Ups Heart RiskEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
BERLIN — Men treated with endocrine therapy for prostate cancer are at increased risk of developing and dying from several types of cardiovascular disease, according to a large observational analysis of 30,642 Swedish patients. (Source: Internal Medicine News)
Source: Internal Medicine News - October 15, 2009 Category: Internal Medicine Authors: PATRICE WENDLING Tags: News Source Type: journals

Standard treatment of female patients with breast cancer decreases substantially for women aged 70 years and older: a German clinical cohort study.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: Our study confirms that substandard treatment increases considerably with age. Omission of radiotherapy had the greatest impact on OAS and DFS in the elderly population. PMID: 19825884 [PubMed - as supplied by publisher] (Source: Ann Oncol)
Source: Ann Oncol - October 12, 2009 Category: Cancer & Oncology Authors: Hancke K, Denkinger MD, König J, Kurzeder C, Wöckel A, Herr D, Blettner M, Kreienberg R Tags: Ann Oncol Source Type: journals

Stage I breast cancer in a regional oncology practice in Israel 2002–2006: Clinicopathologic features, risk estimation and planned therapy of 328 consecutive patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We present the clinicopathologic features and treatment plans of 328 consecutive stage I (T1N0M0) breast cancer patients seen at a regional medical center in Israel. Predicted 10-year mortality risk was calculated using the Adjuvant! Online website. The 21-gene recurrence score (RS) (OncotypeDx™) was obtained on a minority of patients. Eighty-nine per cent of patients had estrogen receptor (ER) and/or progesterone receptor (PgR) positive tumors. In 43.3% of patients history of an invasive malignancy was reported in a first degree relative and in 15.5% specifically breast and/or ovarian cancer was reported. Chemotherapy w...
Source: The Breast - October 12, 2009 Category: Cancer & Oncology Authors: D.B. Geffen, N. Amir, N. Sion-Vardy, S. Ariad, L. Kachko, M. Bayme, B. Delgado, V. Dyomin, S. Argov, M. Koretz Tags: Original Articles Source Type: journals

Stage I breast cancer in a regional oncology practice in Israel 2002-2006: Clinicopathologic features, risk estimation and planned therapy of 328 consecutive patients.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We present the clinicopathologic features and treatment plans of 328 consecutive stage I (T1N0M0) breast cancer patients seen at a regional medical center in Israel. Predicted 10-year mortality risk was calculated using the Adjuvant! Online website. The 21-gene recurrence score (RS) (OncotypeDx) was obtained on a minority of patients. Eighty-nine per cent of patients had estrogen receptor (ER) and/or progesterone receptor (PgR) positive tumors. In 43.3% of patients history of an invasive malignancy was reported in a first degree relative and in 15.5% specifically breast and/or ovarian cancer was reported. Chemotherapy was ...
Source: Breast - October 7, 2009 Category: Cancer & Oncology Authors: Geffen DB, Amir N, Sion-Vardy N, Ariad S, Kachko L, Bayme M, Delgado B, Dyomin V, Argov S, Koretz M Tags: Breast Source Type: journals

Endocrine Therapies and QTc Prolongation.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
QT interval represents the period between the initiation of depolarization and the end of repolarization of the ventricular myocardium. Excessive prolongation of this interval may drive to a potentially fatal ventricular tachyarrhythmia known as "torsades de pointes". Agents used to manage many endocrine disorders have been linked with QTc alterations. Among them, oral antidiabetic agents, lipid lowering and anti-obesity drugs, somatostatin analogues, thyroid and anti-thyroid agents, and adrenal steroids should be considered. Nevertheless, it is very well known that some endocrine diseases are associated with constrain...
Source: Current Drug Safety - October 6, 2009 Category: Drugs & Pharmacology Authors: Gonzalez CD, de Sereday M, Sinay I, Santoro S Tags: Curr Drug Saf Source Type: journals

CRK7 modifies the MAPK pathway and influences the response to endocrine therapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study identifies a novel role for CRK7 in MAPK regulation and resistance to estrogen signaling inhibitors. (Source: Carcinogenesis)
Source: Carcinogenesis - October 6, 2009 Category: Cancer & Oncology Authors: Iorns, E., Martens-de Kemp, S. R., Lord, C. J., Ashworth, A. Tags: CANCER BIOLOGY Source Type: journals

AEterna Zentaris: Thorough QT Trial with Cetrorelix in Benign Prostatic Hyperplasia Meets Primary EndpointEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
QUEBEC CITY, Sept. 30 /PRNewswire-FirstCall/ -- AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported that the 043 Thorough QT (TQT) trial, which... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - October 4, 2009 Category: Pharmaceuticals Source Type: clinical trials

Prostate Cancer Patients On Hormone Therapy At Increased Risk For Various Heart DiseasesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New research has found that hormone therapy used to treat men with advanced prostate cancer is associated with an increased chance of developing various heart problems. Some choices of therapy appear, however, to be less risky than others. Researchers told Europe's biggest cancer congress, ECCO 15 - ESMO 34 [1], in Berlin today (Tuesday 22 September) that the findings of their study, the largest and most comprehensive to date on the issue, indicate that doctors need to start considering heart-related side effects when they prescribe endocrine therapy for prostate cancer and might want to refer patients to a cardiologist be...
Source: Cancercompass News: Prostate Cancer - October 2, 2009 Category: Cancer & Oncology Source Type: news

Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Patients with ER-negative and PR-negative and HER2/neu-amplified breast cancer phenotypes are more likely to experience pCR to neoadjuvant therapy. Although pCR is more frequently observed following neoadjuvant chemotherapy, it is rare following neoadjuvant endocrine therapy. (Source: American Journal of Surgery)
Source: American Journal of Surgery - September 30, 2009 Category: Surgery Authors: Marcus C. Tan, Fatema Al Mushawah, Feng Gao, Rebecca L. Aft, William E. Gillanders, Timothy J. Eberlein, Julie A. Margenthaler Tags: The American Society of Breast Surgeons Source Type: journals

The biology of hormone refractory breast and prostate cancer: An NCI workshop report.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The molecular regulation of growth and progression of hormone refractory breast and prostate cancers remains challenging. The Division of Cancer Biology, NCI organized a small "think tank" style workshop and invited scientists in relevant areas to assess the state of science on the biology of hormone refractory tumors and to identify potential research opportunities to enhance a better understanding of the molecular regulation of these tumors. The meeting, held on May 27-29, 2008 in Bethesda, MD, was co-chaired by Drs. Michael Geoffrey Rosenfeld and Michael Press. While expression of estrogen or progesterone receptors ...
Source: Cancer Biology and Therapy - September 29, 2009 Category: Cancer & Oncology Authors: Mohla S, Stearns V, Sathyamoorthy N, Rosenfeld MG, Nelson P Tags: Cancer Biol Ther Source Type: journals

MMP7 expression regulated by endocrine therapy in ERbeta-positive colon cancer cellsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Our findings suggest that endocrine therapy is an efficient therapy for inhibiting ERbeta-positive colon cancer cell proliferation and migration via down-regulation of MMP7. (Source: Journal of Experimental and Clinical Cancer Research)
Source: Journal of Experimental and Clinical Cancer Research - September 28, 2009 Category: Cancer & Oncology Authors: Yu-Jing FangZhi-Zhong PanLi-Ren LiZhen-Hai LuLi-Yi ZhangDe-Sen Wan Source Type: journals

Pharmacogenomics of Tamoxifen Therapy [Review]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Background: Tamoxifen is a standard endocrine therapy for the prevention and treatment of steroid hormone receptor–positive breast cancer. Content: Tamoxifen requires enzymatic activation by cytochrome P450 (CYP) enzymes for the formation of active metabolites 4-hydroxytamoxifen and endoxifen. As compared with the parent drug, both metabolites have an approximately 100-fold greater affinity for the estrogen receptor and the ability to inhibit cell proliferation. The polymorphic CYP2D6 is the key enzyme in this biotransformation, and recent mechanistic, pharmacologic, and clinical evidence suggests that genetic varian...
Source: Clinical Chemistry - September 27, 2009 Category: Chemistry Authors: Brauch, H., Murdter, T. E., Eichelbaum, M., Schwab, M. Tags: Review Source Type: journals

Hormone Therapy for Prostate Cancer Raises Heart Disease RiskEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
BERLIN (EGMN) - Men treated with endocrine therapy for prostate cancer are at increased risk of developing and dying from several types of cardiovascular disease, according to a large observational analysis... (Source: OncologySTAT Latest News)
Source: OncologySTAT Latest News - September 24, 2009 Category: Cancer & Oncology Source Type: news

Biological determinants of endocrine resistance in breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
erland Endocrine therapies targeting oestrogen action (anti-oestrogens, such as tamoxifen, and aromatase inhibitors) decrease mortality from breast cancer, but their efficacy is limited by intrinsic and acquired therapeutic resistance. Candidate molecular biomarkers and gene expression signatures of tamoxifen response emphasize the importance of deregulation of proliferation (Source: Nature Reviews Cancer)
Source: Nature Reviews Cancer - September 22, 2009 Category: Cancer & Oncology Authors: Elizabeth A. MusgroveRobert L. Sutherland Tags: Review Source Type: journals

Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study [Breast Cancer]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion First-line fulvestrant HD was at least as effective as anastrozole for CBR and ORR and was associated with significantly longer TTP. Fulvestrant HD was generally well tolerated, with a safety profile similar to that of anastrozole. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 20, 2009 Category: Cancer & Oncology Authors: Robertson, Llombart-Cussac, Rolski, Feltl, Dewar, Macpherson, Lindemann, Ellis Tags: Hormonal Therapy, Clinical Trials Breast Cancer Source Type: journals

High-Dose Fulvestrant Helpful Against Breast CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
For first-line endocrine therapy in advanced hormone receptor-positive breast cancer in postmenopausal women, double the approved dose of fulvestrant does at least as well as anastrozole, researchers report in the August 24th issue of the Journal of Clinical Oncology. Reuters Health Information (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - September 9, 2009 Category: Drugs & Pharmacology Tags: Hematology-Oncology Source Type: info

Evaluation of Microtubule-Associated Protein-Tau Expression As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial [Breast Cancer]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion High Tau protein expression is associated with better prognosis in patients treated with adjuvant anthracycline and paclitaxel chemotherapy and endocrine therapy, but there was no significant interaction between Tau expression and paclitaxel benefit. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - September 7, 2009 Category: Cancer & Oncology Authors: Pusztai, Jeong, Gong, Ross, Kim, Paik, Rouzier, Andre, Hortobagyi, Wolmark, Symmans Tags: Translational Oncology, Prognostic Studies Breast Cancer Source Type: journals

Low p27 Expression Predicts Early Relapse and Death in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients Receiving Adjuvant Tamoxifen Therapy.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: Low p27 expression independently predicts early relapse and death in postmenopausal women with early-stage, hormone receptor-positive breast cancer who received adjuvant tamoxifen for 5 years. (Clin Cancer Res 2009;15(18):5888-94). PMID: 19723645 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - August 31, 2009 Category: Cancer & Oncology Authors: Filipits M, Rudas M, Heinzl H, Jakesz R, Kubista E, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Nader A, Stierer M, Gnant MF, Tags: Clin Cancer Res Source Type: journals

Concurrent administration of chemo-endocrine therapy for postmenopausal breast cancer patients.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: The pCR rate of the concurrent administration of chemo-endocrine therapy was not lower than those of past trials, but it remains uncertain whether this positive result was due to the administration of the aromatase inhibiter or our NAC regimen. In order to answer this, we need to make a direct comparison between the concurrent versus sequential administration of the aromatase inhibitor during NAC in a prospective study. PMID: 19728030 [PubMed - as supplied by publisher] (Source: Breast Cancer)
Source: Breast Cancer - August 31, 2009 Category: Cancer & Oncology Authors: Watanabe N, Ootawa Y, Kodama K, Kaide A, Ootsuka N, Matsuoka J Tags: Breast Cancer Source Type: journals

Fulvestrant Shows Benefits in Advanced Breast CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
High-dose fulvestrant, an estrogen receptor antagonist, appears to be at least as effective as the aromatase inhibitor anastrozole as a first-line endocrine therapy in postmenopausal women with advanced hormone receptor-positive breast cancer, according to research published online Aug. 24 in the Journal of Clinical Oncology. (Source: Modern Medicine)
Source: Modern Medicine - August 26, 2009 Category: Journals (General) Source Type: info

Biological determinants of endocrine resistance in breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
erland Endocrine therapies targeting oestrogen action (anti-oestrogens, such as tamoxifen, and aromatase inhibitors) decrease mortality from breast cancer, but their efficacy is limited by intrinsic and acquired therapeutic resistance. Candidate molecular biomarkers and gene expression signatures of tamoxifen response emphasize the importance of deregulation of proliferation (Source: Nature Reviews Cancer)
Source: Nature Reviews Cancer - August 24, 2009 Category: Cancer & Oncology Authors: Elizabeth A. MusgroveRobert L. Sutherland Tags: Review Source Type: journals

A comparison of estrogen receptor SP1 and 1D5 monoclonal antibodies in routine clinical use reveals similar staining results.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study on mostly previously frozen tissue implied that 1D5 fails to identify some women who may benefit from endocrine therapy. The current prospective study compared SP1 and 1D5 immunostaining on routinely processed consecutive cases of breast carcinoma. ER was classified using the same positive threshold used in the prior study (<1% negative; > or = 1% positive). Of 508 carcinomas, 2 were SP1+/1D5-, and none were SP1-/1D5+. Although SP1 is our preferred antibody, with more intense nuclear staining, both MAbs give similar results in tissue from routine clinical samples with discrepant results in fewer than 0.5% ...
Source: American Journal of Clinical Pathology - August 20, 2009 Category: Pathology Authors: Brock JE, Hornick JL, Richardson AL, Dillon DA, Lester SC Tags: Am J Clin Pathol Source Type: journals

Breast cancer cells can switch between estrogen receptor α and ErbB signaling and combined treatment against both signaling pathways postpones development of resistanceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract The majority of breast cancers are estrogen responsive, but upon progression of disease other growth promoting pathways are activated, e.g., the ErbB receptor system. The present study focuses on resistance to the pure estrogen antagonist fulvestrant and strategies to treat resistant cells or even circumvent development of resistance. Limited effects were observed when targeting EGFR and ErbB2 with the monoclonal antibodies cetuximab, trastuzumab, and pertuzumab, whereas the pan-ErbB inhibitor CI-1033 selectively inhibited growth of fulvestrant resistant cell lines. CI-1033 inhibited Erk but not Akt...
Source: Breast Cancer Research and Treatment - August 20, 2009 Category: Cancer & Oncology Tags: Breast Cancer Research and Treatment Source Type: journals

Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Preoperative therapy for DCIS is associated with significant pathologic alterations. These changes may be clinically significant. Further work is needed to identify which women may be the best candidates for such treatment for DCIS, and whether best responders may safely avoid surgical intervention.Trial Registration: ClinicalTrials.gov NCT00290745 (Source: BMC Cancer)
Source: BMC Cancer - August 17, 2009 Category: Cancer & Oncology Authors: Yunn-Yi ChenSandy DeVriesJoseph AndersonJuan LessingRebecca SwainKoei ChinVeronica ShimLaura EssermanFrederic WaldmanE. Shelley Hwang Source Type: journals

AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic HyperplasiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
QUEBEC CITY, Aug. 17 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its North... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 17, 2009 Category: Pharmaceuticals Source Type: clinical trials

AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic HyperplasiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
QUEBEC CITY, Aug. 17 (HSMN NewsFeed) - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ ; the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported Phase 3 results for its North American efficacy... Biopharmaceuticals, UrologyAETERNA ZENTARIS, Z-033, Z-041, cetrorelix, benign prostatic hyperplasia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 17, 2009 Category: Pharmaceuticals Source Type: news

Clinical usefulness of high-dose toremifene in patients relapsed on treatment with an aromatase inhibitor.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: TOR120 was rated excellent in acceptability, and high efficacy was observed when it was used up to third-line treatment for AI-failure cases, although this study may show some selection bias because of the retrospective study. In addition, it was also considered effective for TAM-failure cases. PMID: 19685269 [PubMed - as supplied by publisher] (Source: Breast Cancer)
Source: Breast Cancer - August 14, 2009 Category: Cancer & Oncology Authors: Yamamoto Y, Masuda N, Ohtake T, Yamashita H, Saji S, Kimijima I, Kasahara Y, Ishikawa T, Sawaki M, Hozumi Y, Iwase H Tags: Breast Cancer Source Type: journals